PT - JOURNAL ARTICLE AU - Park, Ik Hyun AU - Jang, Woo Jin AU - Oh, Ju Hyeon AU - Yang, Jeong Hoon AU - Song, Young Bin AU - Hahn, Joo-Yong AU - Choi, Seung-Hyuk AU - Gwon, Hyeon-Cheol AU - Ahn, Chul-Min AU - Yu, Cheol Woong AU - Kim, Hyun-Joong AU - Bae, Jang-Whan AU - Kwon, Sung Uk AU - Lee, Hyun-Jong AU - Lee, Wang Soo AU - Jeong, Jin-Ok AU - Park, Sang-Don TI - Non-Culprit Left Main Coronary Artery Disease in Acute Myocardial Infarction Complicated by Cardiogenic Shock AID - 10.1101/2022.10.13.22281047 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.13.22281047 4099 - http://medrxiv.org/content/early/2022/10/14/2022.10.13.22281047.short 4100 - http://medrxiv.org/content/early/2022/10/14/2022.10.13.22281047.full AB - Objectives We evaluated the clinical impact of residual non-culprit left main coronary artery disease (LMCAD) on prognosis in patients undergoing emergent percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) complicated by cardiogenic shock (CS).Methods A total of 429 patients who underwent PCI for AMI complicated by CS was enrolled from 12 centers in the Republic of Korea. The patients were divided into two groups according to presence of non-culprit LMCAD or not: the LMCAD non-culprit group (n = 43) and the no LMCAD group (n = 386). Primary outcome was major adverse cardiac event (MACE, defined as a composite of cardiac death, myocardial infarction, or repeat revascularization). Propensity score matching analysis was performed to reduce selection bias and potential confounding factors.Results During a 12-month follow-up, a total of 168 MACEs occurred (LMCAD non-culprit group, 17 [39.5%] vs. no LMCAD group, 151 [39.1%]). Multivariate analysis revealed no significant difference in the incidence of MACE at 12 months between the LMCAD non-culprit and no LMCAD groups (adjusted hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.56 to 1.58, p = 0.817). After propensity score matching, the incidence of MACE was still similar between the two groups(HR 1.07; 95% CI 0.49 to 2.36; p = 0.857). The similarity of MACEs between the two groups was consistent across a variety of subgroups.Conclusions After adjusting for baseline differences, residual non-culprit LMCAD does not appear to increase the risk of MACEs at 12 months in patients undergoing emergent PCI for AMI complicated by CS.Competing Interest StatementThe authors have declared that no competing interests exist.Funding StatementThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved and the requirement for informed consent from the individual patients was waived by the Institutional Review Board of Samsung Medical Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.AMIacute myocardial infarctionCScardiogenic shockECMOextracorporeal membrane oxygenationLMCADleft main coronary artery diseaseMACEmajor adverse cardiac eventPCIpercutaneous coronary interventionSTEMIST-segment elevation myocardial infarction